These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17695809)

  • 21. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J
    Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
    [No Abstract]   [Full Text] [Related]  

  • 22. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular basis for therapeutic choices in heart failure.
    Opie LH
    Circulation; 2004 Oct; 110(17):2559-61. PubMed ID: 15505109
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Ito S
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 26. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM; Sanoski CA; Spinler SA
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
    Sanada S; Kitakaze M
    Nihon Rinsho; 2003 May; 61(5):821-6. PubMed ID: 12755009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy.
    Dalla Vestra M; Simioni N; Masiero A
    Int Urol Nephrol; 2009; 41(1):119-26. PubMed ID: 18958580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ACE inhibitors vs. ARBs for patients with diabetic kidney disease.
    Bailey J
    Am Fam Physician; 2007 Jul; 76(1):68-9. PubMed ID: 17668841
    [No Abstract]   [Full Text] [Related]  

  • 32. [RAS blockade].
    Jin C; Ito S
    Nihon Rinsho; 2004 Oct; 62(10):1880-4. PubMed ID: 15500134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
    Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
    Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of spironolactone on nephron function in patients with diabetic nephropathy.
    Ustundag A; Tugrul A; Ustundag S; Sut N; Demirkan B
    Ren Fail; 2008; 30(10):982-91. PubMed ID: 19016150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

  • 36. [Atrial fibrillation: potential therapeutic interventions in the renin-angiotensin-aldosterone system].
    Dabrowski R; Szwed H
    Kardiol Pol; 2007 Apr; 65(4):440-5. PubMed ID: 17530565
    [No Abstract]   [Full Text] [Related]  

  • 37. [Renoprotective effect of Blood pressure control on progression of diabetic retinopathies].
    Katayama S
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():389-93. PubMed ID: 15999740
    [No Abstract]   [Full Text] [Related]  

  • 38. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?
    van de Wal RM; van Veldhuisen DJ; van Gilst WH; Voors AA
    Eur Heart J; 2005 Nov; 26(22):2361-7. PubMed ID: 16105846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing diabetic nephropathy: recent studies.
    Lit YZ; Meyer T
    Curr Opin Nephrol Hypertens; 2006 Mar; 15(2):111-6. PubMed ID: 16481875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renin-angiotensin system].
    Ito S
    Nihon Jinzo Gakkai Shi; 2007; Suppl 50th Ann():103-6. PubMed ID: 17899835
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.